| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8735301 | Hepatobiliary & Pancreatic Diseases International | 2017 | 7 Pages |
Abstract
Intravenous moxifloxacin is not inferior to intravenous ceftriaxone for the prophylactic treatment of post-ERCP cholangitis and cholangitis-associated morbidity.
Related Topics
Health Sciences
Medicine and Dentistry
Hepatology
Authors
Nam Hee Kim, Hong Joo Kim, Ki Bae Bang,